Citeline Podcasts

Citeline
  • 4,1 (28)
  • KINH DOANH
  • HẰNG NGÀY
Citeline Podcasts

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

  1. 유럽 바이오기업, 자금조달의 현주소는? (Korean-language podcast)

    1 NGÀY TRƯỚC

    유럽 바이오기업, 자금조달의 현주소는? (Korean-language podcast)

    관세와 무역 장벽의 출현, 정책 변화 등으로 올해 유럽 바이오기업들의 자금조달이 쉽지 않은 상황이라는 In Vivo 기사를 요약한 내용입니다. https://insights.citeline.com/in-vivo/market-intelligence/the-360-degrees-of-european-biotech-financing-in-2025-KZUNCOS3GZAYLBPGFTLJUBY7SY/ Join Seoul-based Scrip and Pink Sheet editor Jung Won Shin in this Korean-language mini podcast on recent biopharma industry topics. Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini

    4 phút
  2. Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

    1 NGÀY TRƯỚC

    Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

    Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

    34 phút
  3. Unpacking EU Omnibus And Its Impact On Sustainability: With CEN Group’s Jasper Crone

    2 NGÀY TRƯỚC

    Unpacking EU Omnibus And Its Impact On Sustainability: With CEN Group’s Jasper Crone

    The European Commission has put forward a series of proposals designed to simplify European Union sustainability rules and boost the region’s competitiveness. As a result, application dates for EU due diligence and sustainability reporting requirements have been delayed by two years. Other proposals such as reducing the frequency of reporting and narrowing the scope of supply chains are still subject to trilogue negotiation. In the first of two Over the Counter episodes, CEN Group director Jasper Crone returns to the podcast to explain what might change, where he thinks this is all coming from and why companies should consider getting ready for new sustainability reporting rules even if they are no longer directly affected. Timestamps: 2:00 – Introductions 4:30 – EU sustainability reporting regulation recap 7:20 – Omnibus simplification package 12:00 – Simplification, or confusion? 19:00 – Where’s this all coming from? 23:30 – Why sustainability reporting is still good for business 25:40 – What’s all this got to do with competitiveness? Guest Bio: Jasper Crone is a Director at CEN-ESG, a corporate sustainability consultancy which helps businesses maximise their corporate sustainability potential, improving performance and ESG disclosure. Crone leads on several client teams, covering the implementation of internal controls and sustainability data, setting sustainability and net zero targets and developing programmes for implementation and operationalisation of objectives. He is experienced in sustainability reporting and the CEN-ESG assists clients with all aspects of sustainability reporting, whether regulatory, investor or customer driven. He brings a range of skills from 20 years of experience in the financial markets, in both the investment banking and investment management industries. He has a BSc in Biology from University of Bristol and is a CFA charter holder. You can contact Jasper via email: jasper@cen-esg.com

    30 phút
  4. Scrip's Five Must-Know Things - 16 June 2025

    2 NGÀY TRƯỚC

    Scrip's Five Must-Know Things - 16 June 2025

    Audio roundup of selected biopharma industry content from Scrip over the business week ended 13 June 2025. In this episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-BC44NPMNMNGMXP5X4STR4ZAFU4/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

    15 phút
  5. Drug Fix: The US and Ex-US Impact Of Most-Favored Nation Drug Pricing

    4 NGÀY TRƯỚC

    Drug Fix: The US and Ex-US Impact Of Most-Favored Nation Drug Pricing

    Pink Sheet Executive Editor Derrick Gingery, Senior Writer Francesca Bruce, Senior Editor Cathy Kelly and Editor-in-Chief Nielsen Hobbs consider European officials’ opinions of President Trump’s Most Favored Nation drug pricing proposal (:29), the uncertainty the plan has created and could create for the pharmaceutical industry (22:48), as well as its potential impact on the both sides of the Atlantic Ocean (27:42). More On These Topics From The Pink Sheet ‘Brainless’ US MFN Policy Could Drive Pharma Investment To Europe: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/brainless-us-mfn-policy-could-drive-pharma-investment-to-europe-Z3FC7WBPKNF2LLG4YVZK3RBDUA/ US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany: https://insights.citeline.com/pink-sheet/geography/europe/us-most-favored-nation-pricing-could-be-game-changer-for-drug-access-in-germany-XFXD72XUSBE7VNLRMRSRQQGU5Q/ US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine’: https://insights.citeline.com/pink-sheet/geography/europe/us-most-favored-nations-policy-higher-drug-spending-in-germany-is-difficult-to-imagine-QYQGDAMNH5A3HK4YWHUYFJCWME/ Could EU Collective Procurement Counter US Most Favored Nation Policy?: https://insights.citeline.com/pink-sheet/could-eu-collective-procurement-counter-us-most-favored-nation-policy-WPQOHPWQ3NF55NYDKT5KMU7AEY/ US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In Europe: https://insights.citeline.com/pink-sheet/us-most-favored-nations-drug-pricing-policy-will-jeopardize-innovation-in-europe-TR52C5V6GVDSJBOTCEJ7T74FB4/ New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France: https://insights.citeline.com/pink-sheet/risk-sharing-agreements-greater-transparency-in-pricing-what-us-most-favored-nations-policy-could-OYEHJIF6LJCQZDL6VJHATV77JA/ Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/crisis-or-opportunity-us-mfn-policy-could-test-japans-appetite-for-reforms-3OTVRHXSOFFIJARSNHPWZ7SBJ4/

    35 phút
  6. Citeline Japan Awards 2025 - Entry Deadline Approaching! (Bilingual English/Japanese)

    6 NGÀY TRƯỚC

    Citeline Japan Awards 2025 - Entry Deadline Approaching! (Bilingual English/Japanese)

    The 14 July entry deadline for the Citeline Japan Awards 2025 in Tokyo on 21 October is fast approaching! Join Ian Haydock and Lisa Takagi in this bilingual mini podcast as they outline the event and the various Award categories. (Japanese starts at 2:20.) More information on categories, entry criteria, table bookings and sponsorship opportunities here: English: https://www.citeline.com/en/awards/citelinejapanawards) Japanese: https://www.citeline.com/ja-jp/awards/citelinejapanawards)

    4 phút
  7. Through Thick and Thin: Funding the Future with Grit

    6 NGÀY TRƯỚC

    Through Thick and Thin: Funding the Future with Grit

    In a tough market, biotech is racing to change the rules. This episode reveals how AI, real-world data, and strategic partnerships are reshaping drug development. Is reinvention biotech’s last hope?

    15 phút
  8. First Sparks: Falling for Innovation in a Harsh Market

    6 NGÀY TRƯỚC

    First Sparks: Falling for Innovation in a Harsh Market

    In this first episode of the series, small biotech companies are facing tough times, shrinking funding and uncertain futures. But beneath the surface, quiet forces of innovation and resilience are rising. We explore how these sparks of hope might just light the way to a new breakthrough.

    10 phút
Xem tất cả (526)

4,1
/5
28 Xếp hạng

Giới Thiệu

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Thông Tin

  • Nhà sáng tạo
    Citeline
  • Năm hoạt động
    2014 - 2025
  • Tập
    526
  • Xếp hạng
    Sạch
  • Bản quyền
    © All rights reserved
  • Trang web chương trình
    Citeline Podcasts

Có Thể Bạn Cũng Thích

Bạn cần đăng nhập để nghe các tập có chứa nội dung thô tục.

Luôn cập nhật thông tin về chương trình này

Đăng nhập hoặc đăng ký để theo dõi các chương trình, lưu các tập và nhận những thông tin cập nhật mới nhất.
Chọn quốc gia hoặc vùng

Châu Phi, Trung Đông và Ấn Độ

Châu Á Thái Bình Dương

Châu Âu

Châu Mỹ Latinh và Caribê

Hoa Kỳ và Canada